Endo, Novartis begin Voltaren gel licensing deal

Share this article:
Endo Pharmaceuticals has entered into a licensing agreement with Novartis to obtain the exclusive US marketing rights for the prescription medicine Voltaren Gel (diclofenac sodium topical gel) 1%.

Endo said it expects to commercialize Voltaren Gel initially using one of its two specialty sales forces, consisting of 160 reps, prior to executing a full physician launch in late May, with an additional 275 contract sales representatives targeting primary care physicians who prescribe NSAIDs and Cox-2s.
Voltaren Gel received FDA approval in October 2007, being granted marketing exclusivity in the US as a prescription medicine at least until October 2010.

Endo estimates US peak annual sales for Voltaren Gel as an osteoarthritis pain treatment in the range of $250-300 million.

Under the terms of the five-year agreement with Novartis, Endo will make an upfront cash payment of $85 million.

Novartis is also eligible to receive a one-time milestone payment of $25 million if annual sales exceed $300 million. Under the deal, Novartis will receive royalties on the net sales of Voltaren Gel in the US and will supply this product to Endo.
Share this article:

Email Newsletters

More in News

Five things for pharma marketers to know: Friday, August 22

Five things for pharma marketers to know: Friday, ...

Two new indications give Eliquis more juice, a new rule is making hydrocodone harder to get and the ALS Ice Bucket Challenge highlights a controversial aspects of drug discovery and ...

Lilly takes on Amgen's Enbrel

Lilly takes on Amgen's Enbrel

Phase-III tests indicate Lilly's experimental treatment bests Amgen's for moderate-to-severe plaque psoriasis.

GSK Ellipta franchise expands

GSK Ellipta franchise expands

The FDA has approved Arnuity Ellipta for asthma.